Show simple item record

dc.contributor.authorSchmid, TAen_US
dc.contributor.authorGore, MEen_US
dc.date.accessioned2017-04-13T09:51:35Z
dc.date.issued2016-12en_US
dc.identifier.citationTherapeutic advances in urology, 2016, 8 (6), pp. 348 - 371en_US
dc.identifier.issn1756-2872en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/591
dc.identifier.eissn1756-2880en_US
dc.identifier.doi10.1177/1756287216663979en_US
dc.description.abstractSunitinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that targets various receptors, including vascular endothelial growth factor receptors (VEGFRs). Sunitinib received approval in 2006 and became a standard treatment option in the first-line treatment of metastatic renal cell cancer (mRCC) after a phase III trial showed superiority compared with interferon alpha (IFN-α). Sunitinib has also shown activity in second-line treatment in several trials. Most of the combination trials with sunitinib with various agents have led to considerable toxicity without improving efficacy. Sunitinib alone causes significant side effects and has a distinct profile with diarrhoea, hypertension, skin effects hypothyroidism, fatigue and nausea of special interest. The recommended dose of sunitinib in mRCC is 50 mg orally daily for 4 weeks, followed by 2 weeks off treatment (4/2 schedule). An alternative 2 weeks on, 1 week off schedule (2/1 schedule) seems to be of similar efficacy and better tolerability and could be more widely used in the future. An intermittent treatment strategy with a stop in remission and re-induction after progression showed efficacy in smaller trials and is currently being evaluated in a phase III trial. Direct comparison of sunitinib with pazopanib in first-line treatment showed a similar efficacy for both TKIs with a distinct toxicity profile. Data from two phase II trials showed that sunitinib has also activity in non-clear cell cancer and is an option due to a lack of better alternatives. Currently, after immune checkpoint inhibitors have shown very promising results in the second-line treatment of RCC, they are being tested in a number of phase III trials in the first-line setting. The future will show the position of sunitinib in the first-line treatment of RCC in the era of the immune checkpoint inhibitors.en_US
dc.formatPrint-Electronicen_US
dc.format.extent348 - 371en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_US
dc.titleSunitinib in the treatment of metastatic renal cell carcinoma.en_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1177/1756287216663979en_US
rioxxterms.licenseref.startdate2016-12en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfTherapeutic advances in urologyen_US
pubs.issue6en_US
pubs.notes12 monthsen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume8en_US
pubs.embargo.terms12 monthsen_US
dc.contributor.icrauthorGore, Martinen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record